BACKGROUND:Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study. METHODS AND RESULTS: HF-ACTION was a randomized, controlled trial of exercise training in patients with chronic heart failure caused by left ventricular systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. Higher galectin-3 levels were associated with other measures of heart failure severity, including higher New York Heart Association class, lower systolic blood pressure, higher creatinine, higher amino-terminal proB-type natriuretic peptide (NTproBNP), and lower maximal oxygen consumption. In unadjusted analysis, there was a significant association between elevated galectin-3 levels and hospitalization-free survival (unadjusted hazard ratio, 1.14 per 3-ng/mL increase in galectin-3; P<0.0001). In multivariable modeling, the prognostic impact of galectin-3 was significantly attenuated by the inclusion of other known predictors, and galectin-3 was no longer a significant predictor after the inclusion of NTproBNP. CONCLUSIONS:Galectin-3 is elevated in ambulatory heart failure patients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
RCT Entities:
BACKGROUND:Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failurepatients enrolled in the HF-ACTION study. METHODS AND RESULTS: HF-ACTION was a randomized, controlled trial of exercise training in patients with chronic heart failure caused by left ventricular systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. Higher galectin-3 levels were associated with other measures of heart failure severity, including higher New York Heart Association class, lower systolic blood pressure, higher creatinine, higher amino-terminal proB-type natriuretic peptide (NTproBNP), and lower maximal oxygen consumption. In unadjusted analysis, there was a significant association between elevated galectin-3 levels and hospitalization-free survival (unadjusted hazard ratio, 1.14 per 3-ng/mL increase in galectin-3; P<0.0001). In multivariable modeling, the prognostic impact of galectin-3 was significantly attenuated by the inclusion of other known predictors, and galectin-3 was no longer a significant predictor after the inclusion of NTproBNP. CONCLUSIONS:Galectin-3 is elevated in ambulatory heart failurepatients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.
Authors: Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto Journal: J Am Coll Cardiol Date: 2006-08-28 Impact factor: 24.094
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong Journal: Circulation Date: 2008-12-15 Impact factor: 29.690
Authors: Dirk J A Lok; Peter Van Der Meer; Pieta W Bruggink-André de la Porte; Erik Lipsic; Jan Van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen Journal: Clin Res Cardiol Date: 2010-02-04 Impact factor: 5.460
Authors: Lori B Daniels; Paul Clopton; Gail A Laughlin; Alan S Maisel; Elizabeth Barrett-Connor Journal: Am Heart J Date: 2014-02-18 Impact factor: 4.749
Authors: Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola Journal: J Card Fail Date: 2015-11-10 Impact factor: 5.712